Aprea Therapeutics, Inc. 8-K

What Happened

• Aprea Therapeutics, Inc. (NASDAQ: APRE) filed an 8-K on January 23, 2026 reporting that Nasdaq’s Listing Qualifications Department sent a deficiency letter because the company’s closing bid price has been below the $1.00 minimum for the last 30 consecutive business days.
• The letter does not remove the stock from the Nasdaq Capital Market; APRE will continue trading. Nasdaq has given Aprea a 180-calendar-day compliance period, until July 22, 2026, to regain the minimum $1.00 bid price.

Key Details

• Deficiency notice date: January 23, 2026.
• Minimum bid price requirement: $1.00 per share (Nasdaq Listing Rule 5550(a)(2)).
• Compliance period: 180 calendar days ending July 22, 2026; regain compliance by showing a closing bid of at least $1.00 for 10 consecutive business days.
• If not cured, the company may be eligible for a second 180-day period if it meets other listing standards (market value of publicly held shares and initial listing criteria) and notifies Nasdaq of intent to cure; failure to cure could lead to delisting, with the right to appeal.

Why It Matters

• A Nasdaq deficiency notice signals the company must raise its share price or meet other listing standards to avoid possible delisting, which could reduce liquidity and investor access.
• Management said it will monitor the situation and may consider options such as a reverse stock split to regain compliance, but there is no assurance it will succeed. Investors should note the timeline (through July 22, 2026) and that trading continues under the ticker APRE.